



IN CASE OF EMERGENCY Emergency Phone: (614) 276-4000

Material Safety Data Sheet

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION		
Common/Trade Name: Imipramine Pamoate Capsules		
Chemical Name: 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine 4, 4'-methylenebis-(3-hydroxy-2-naphthoate) (2:1)		
Synonyms: None		
Molecular Formula: (C ₁₉ H ₂₄ N ₂)•C ₂₃ H ₁₆ O ₆		
Molecular Weight: 949.21		
CAS No: 10075-24-8		
Chemical Family: Tricyclic antidepressant		
Product Use: Treatment of depression		
Manufacturer's Name: Boehringer Ingelheim Roxane Inc.		
Address: 1809 Wilson Road Columbus, Ohio 43228		
2. COMPOSITION / INFORMATION ON INGREDIENTS		
Composition	CAS#	Exposure Limit
Imipramine Pamoate (active ingredient)	10075-24-8	None established
<i>REFER to PHYSICIAN'S DESK REFERENCE for common components present as <1%</i>		
3. HAZARDS IDENTIFICATION		
Emergency Overview	Physical State: Capsules The 75 mg capsules are light caramel opaque and contain a light yellow to yellow powder with "54 591" printed on the capsule. The 100 mg capsules are light caramel opaque/yellow opaque and contain a light yellow to yellow powder with "54 758" printed on the capsule. The 125 mg capsules are light caramel opaque/ivory opaque and contain a light yellow to yellow powder with "54 466" printed on the capsule. The 150 mg capsules are light caramel opaque and contain a light yellow to yellow powder with "54 161" printed on the capsule. Odor: No data available WARNING! May be harmful if swallowed. Accidental ingestion of large amounts may be harmful.	
Primary Route(s) of Entry	Ingestion	
Potential Health Effects:	Inhalation: Not expected to be an inhalation hazard in final pharmaceutical form. Eye Contact: Not expected to be a hazard to the eye in final pharmaceutical form. Skin Contact: Not expected to be a hazard to the skin. Can cause hypersensitive reactions resulting in rash, redness, itching and inflammation. Ingestion: May be harmful if ingested. Ingestion may cause confusion, anxiety, drowsiness, nausea, vomiting and constipation.	

Toxicity Data:	See Section 11	
Effects of Overexposure:	The potential for exposure is reduced in finished pharmaceutical form. Overexposure by ingestion may cause drowsiness, stupor, restlessness and vomiting. Severe overexposure may cause cardiac dysrhythmias, severe hypotension, convulsions, CNS depression including coma and even death.	
Target Organs:	Brain	
4. FIRST AID MEASURES		
Eye Exposure	Any material that contacts the eye should be washed out immediately with water. If easy to do, remove contact lenses if worn. Get medical attention if symptoms persist.	
Skin Exposure	Wash with soap and water. Get medical attention if symptoms occur.	
Ingestion	Call a physician or poison control center immediately.	
Inhalation	Should not pose a hazard in the final form. If breathing is difficult, move to fresh air. Get medical attention immediately.	
5. FIRE AND EXPLOSION HAZARDS		
Flammability	Lower: N/A	Upper: N/A
Flash Point	Not Applicable	
Extinguishing Media	Use water spray, dry chemical, carbon dioxide or material appropriate for fire in surrounding area	
Special Fire Fighting Procedures	Wear full protective clothing and self-contained breathing apparatus.	
Unusual Fire/Explosion Hazards	Not Applicable	
Hazardous Combustion Products	Carbon dioxide, carbon monoxide, oxides of nitrogen	
6. ACCIDENTAL RELEASE INFORMATION		
STEPS TO BE TAKEN IF SIGNIFICANT QUANTITIES OF PRODUCT IS SPILLED: Use appropriate personal protective equipment (see Section 8). Sweep up and containerize spill material in a compatible container. Dispose according to applicable regulations. Incineration of the waste at an approved facility is recommended.		
7. PRECAUTIONS FOR SAFE HANDLING AND USE		
Precautions Handling Significant Quantities of Product:	Observe good industrial hygiene practices.	
Storage	Store at 20° to 25°C (68° to 77°F). Keep container closed tightly. Store away from foodstuffs.	
8. CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT		
Exposure Limits	None	
Engineering Controls	Not required when handling capsules or containers. Ventilation should be matched to conditions.	
Respiratory Protection	Not required when handling capsules or containers. NIOSH/MSHA approved respirators for protection should be used if respirators are found to be necessary. Ventilation should be matched to conditions.	
Personal Protection	Not required when handling capsules. If containers are compromised or exposure is likely wear: Goggles, Lab Coat, Gloves	
Recommended Facilities	Eye wash, washing facilities	
9. PHYSICAL / CHEMICAL CHARACTERISTICS		

Appearance	Light caramel opaque or light caramel opaque/yellow opaque or light caramel opaque/ivory opaque capsules containing a light yellow to yellow powder	Melting point	Not available	Solubility in water	Not available
Odor	Not available	Boiling point	Not available	Specific Gravity	Not available
Taste	Not available	Vapor Pressure	Not available	Flashpoint	Not available
pH	Not available	Density	Not available	Flammability Limits	Not available

10. STABILITY AND REACTIVITY DATA

Stability	Stable
Incompatibility	None known
Hazardous Decomposition	Oxides of carbon, oxides of nitrogen
Conditions to Avoid	Excessive heat, light
Hazardous Polymerization	Will not occur.

11. TOXICOLOGICAL INFORMATION**Acute Toxicity:****Active Ingredient:**

LD50 Oral (rat): 1100 - 1850 mg/kg

LD50 Oral (mouse): 2185 mg/kg

Carcinogenicity: Not listed as a carcinogen by NTP, IARC Monographs or OSHA.

12. ENVIRONMENTAL IMPACT INFORMATION

No information is currently available on the environmental impact of this product.

13. DISPOSAL INFORMATION

Waste Disposal Considerations: Dispose of material according to federal, state and local disposal regulations or company operating procedures. Disposal by incineration is recommended.

At home: Discard away from children's reach.

14. TRANSPORTATION INFORMATION

This product is not subject to the regulations for the safe transport of hazardous chemicals.

DOT: Not regulated

TDG: Not regulated

IATA: Not regulated

IMDG: Not regulated

15. REGULATORY INFORMATION

DEA: Imipramine Pamoate is not a controlled substance.

FDA: Imipramine Pamoate is an approved prescription medication.

Inventory Status: This material is not listed on the US TSCA Inventory. Therefore, it can only be used for TSCA exempt purposes such as R&D or drug use.

This material is not listed on the DSL Inventory but is exempt.
16. OTHER DATA
ABBREVIATIONS: N/A – not applicable
Prepared by: Boehringer Ingelheim Roxane, Inc.
References: <ol style="list-style-type: none">1. Imipramine Pamoate Capsules, Package Insert, Boehringer Ingelheim Roxane, Inc. , Columbus, Ohio2. RTECS No. HO2450000 – 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine 4, 4'-methylenebis-(3-hydroxy-2-naphthoate) (2:1)3. Ariel Websight. Regulatory and ChemExpert Database.4. PDR – Physicians Desk Reference
Date: 01/07/2010 - New MSDS
SEE CURRENT PACKAGE INSERT FOR FURTHER INFORMATION

The information provided is believed to be complete and accurate. If this product is combined with other materials, deteriorates or becomes contaminated, it may pose hazards not mentioned in this MSDS. It is the users' responsibility to use the information according to the application. Boehringer Ingelheim Roxane, Inc. assumes no responsibility or liability resulting from the use of this information.